Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up

Documents similaires

• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  par: Caorsi, R, et autres
  Publié: (2011)
• The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
  par: Caorsi, Roberta, et autres
  Publié: (2013)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  par: Bibalo, C, et autres
  Publié: (2011)
• Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
  par: Toker, Ori, et autres
  Publié: (2010)
• The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
  par: Svetlana Olegovna Salugina, et autres
  Publié: (2014-12-01)